Drugs / SRT2379
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01416376 Comparator | Aug → Dec 2011 | infectious disease with sepsis | Sirtris, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT01262911 Comparator | Feb → Apr 2011 | infectious disease with sepsis | Sirtris, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT01018628 Comparator | Dec 2009 → Aug 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRT2379 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01262911 ↗ |
| Action | Activate | “activator of SIRT1” NCT01262911 ↗ |
| Modality | Small molecule | “potent small molecule activator of SIRT1” NCT01262911 ↗ |
| Route | Oral | “SRT2379 administered orally.” NCT01018628 ↗ |
| Target | SIRT1 | “potent small molecule activator of SIRT1” NCT01262911 ↗ |